Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Transplant Medicine
Daclizumab, tacrolimus, and mycophenolate mofetil are safe for second transplant
November 24th, 2003
Organ transplantation patients who had undergone previous organ transplantation were given dacluzimab, tacrolimus, and mycophenolate mofetil therapy; at 1 year there was no increased risk of rejection. "Clinical trials using daclizumab as induction therapy in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) have been shown to reduce the incidence of acute rejection episodes in solid organ transplantation. In an attempt to obtain a low rejection rate, we proceeded with the use of daclizumab as induction therapy, in combination with TAC and MMF, for recipients with previous transplants," scientists writing in the journal Clinical Transplantation...
Source: Obesity & Diabetes Week (2003-11-24)
|
